Last verified: April 2026

Cannabichromene (CBC): The Neurogenesis Candidate

CBC is the third most abundant cannabinoid in some cannabis chemotypes, produced via the CBCA synthase pathway from CBGA. Unlike THC, CBC has minimal affinity for CB1 or CB2 at standard concentrations. Its primary molecular target is the ion channel TRPA1 (transient receptor potential ankyrin 1), where CBC acts as a potent agonist with an EC50 of approximately 90 nM — making it one of the most potent known naturally occurring TRPA1 activators.

TRPA1 is a pain-sensing ion channel expressed in sensory neurons, where it responds to noxious cold, inflammatory mediators, and environmental irritants (mustard oil, tear gas, cigarette smoke). TRPA1 activation initially sensitizes pain pathways, but sustained agonism can produce desensitization — a phenomenon that may underlie CBC’s reported analgesic effects in animal models, analogous to capsaicin’s mechanism at TRPV1.

CBC also interacts with TRPV1 and TRPV4 channels, though with lower potency than at TRPA1. Additionally, CBC inhibits endocannabinoid reuptake, potentially increasing local anandamide and 2-AG concentrations at their sites of action.

The Neurogenesis Study

The most cited CBC finding comes from Shinjyo and Di Marzo, published in Neurochemistry International in 2013. The study tested CBC on neural stem/progenitor cells (NSPCs) derived from adult mouse subventricular zone tissue and found that CBC promoted the differentiation of NSPCs into astroglial cells (astrocytes) and increased the viability of developing brain cells in culture. The authors suggested that CBC might support adult neurogenesis — the process of generating new neurons in the adult brain, which occurs primarily in the hippocampal dentate gyrus and subventricular zone.

This study has been widely promoted in cannabis media as evidence that CBC “grows new brain cells.” The critical caveats:

• This was an in vitro study — cells in a dish, not an intact brain
• The differentiation was toward astrocytes, not neurons — astrocytes are glial support cells, not the signaling cells that constitute “brain cells” in popular understanding
• In vitro neurogenesis findings have a poor track record of translating to in vivo effects, because the brain microenvironment imposes constraints that cell culture does not
• No in vivo follow-up studies confirming CBC-enhanced neurogenesis in living animals have been published
• No human studies of CBC for any neurological indication exist

The study is scientifically legitimate and the finding is interesting. But “CBC promoted astrocyte differentiation in murine NSPC culture” and “CBC grows new brain cells” are fundamentally different statements. The gap between them is the gap that separates science from marketing.

Tetrahydrocannabivarin (THCV): The Dose-Dependent Switch

THCV is a propyl (3-carbon side chain) analog of THC, compared to THC’s pentyl (5-carbon) side chain. This seemingly minor structural difference produces a pharmacological switch that makes THCV unique among phytocannabinoids: its effect at CB1 is dose-dependent and direction-reversing.

• At low doses, THCV acts as a CB1 antagonist/inverse agonist — blocking the receptor and potentially reducing appetite, which has generated interest in THCV as a weight-management compound
• At higher doses, THCV shifts to CB1 agonist activity, producing mild psychoactive effects similar to but shorter in duration than THC

This biphasic receptor pharmacology is unusual and has made THCV a compound of considerable research interest, particularly for metabolic conditions.

The Diabetes Phase 2 Trial

The most significant clinical evidence for THCV comes from a Phase 2 randomized controlled trial published by Khalid Jadoon and colleagues in Diabetes Care in 2016. The study enrolled 62 patients with type 2 diabetes (non-insulin-treated) in a 5-arm, double-blind, placebo-controlled design testing CBD (100 mg bid), THCV (5 mg bid), a 1:1 CBD:THCV combination (5 mg + 5 mg bid), and a 20:1 CBD:THCV combination (100 mg + 5 mg bid) versus placebo over 13 weeks.

Key findings for THCV (5 mg twice daily):

• Significantly decreased fasting plasma glucose compared to placebo
• Improved pancreatic β-cell function (HOMA2B index)
• Increased adiponectin levels (an insulin-sensitizing adipokine)
• Decreased fasting insulin — consistent with improved insulin sensitivity
• No significant effect on body weight — despite the theoretical expectation from CB1 antagonism, the 5 mg bid dose did not produce weight loss. This may reflect the dose being too low to produce sufficient systemic CB1 antagonism to affect appetite circuits, or it may indicate that THCV’s metabolic effects operate through insulin-sensitizing pathways independent of appetite suppression

This is a legitimate, well-designed Phase 2 clinical trial with statistically significant results on metabolically relevant endpoints. It represents the strongest clinical evidence for any minor cannabinoid other than CBD. However, Phase 2 results do not constitute proof of efficacy — they support advancement to larger Phase 3 trials, which have not yet been conducted for THCV.

Cannabidivarin (CBDV): The Autism Candidate

CBDV is the propyl analog of CBD (3-carbon side chain instead of 5-carbon). Like CBD, CBDV shows minimal CB1/CB2 affinity and instead acts primarily through TRPV1 and TRPV2 channels, TRPA1, and potentially GPR55. Its anticonvulsant properties were demonstrated in preclinical seizure models, and it has been investigated as a potential treatment for epilepsy alongside Epidiolex.

GW Pharmaceuticals (now Jazz Pharmaceuticals) advanced CBDV into clinical trials for autism spectrum disorder (ASD), based on preclinical data suggesting effects on excitatory/inhibitory neurotransmitter balance and repetitive behaviors in mouse models. Phase 2 trials have been completed, but results have been mixed, and CBDV has not achieved the clear efficacy signal that Epidiolex demonstrated in epilepsy. Development continues, but the ASD indication remains unproven.

CBDV has also shown antiemetic properties in preclinical models, potentially through 5-HT1A receptor modulation — the same mechanism implicated in CBD’s antiemetic effects.

The Minor Cannabinoid Research Problem

The minor cannabinoids collectively illustrate a structural problem in cannabis research. Each has an intriguing preclinical profile. Each has plausible mechanisms of action. Each has been the subject of enthusiastic industry interest and consumer product development. But the pipeline from preclinical observation to clinical evidence is long, expensive, and uncertain:

• CBC: zero human clinical trials
• THCV: one Phase 2 trial (diabetes), no Phase 3
• CBDV: Phase 2 trials in progress (autism), no Phase 3 approvals

Meanwhile, all three are commercially available in consumer products with health-related marketing claims. The regulatory gap between pharmaceutical development (where a compound must prove efficacy and safety through rigorous trials before marketing) and the consumer cannabinoid market (where products can be sold with vague “wellness” claims under DSHEA exemptions or state hemp laws) means that marketing consistently precedes evidence.

This is not an argument against minor cannabinoid research — the pharmacology is genuinely interesting and may yield clinically useful drugs. It is an argument for intellectual honesty about what the current evidence does and does not support.

THCV significantly decreased fasting plasma glucose and improved pancreatic beta-cell function in type 2 diabetes, but produced no significant change in body weight at the dose tested.

Jadoon et al., Diabetes Care, 2016